In the war against bioterror, genomic companies are becoming more noticeable. Consider: Maxygen has received grants from DARPA for its MolecularBreeding technologies, which promise rapidly to deliver antigens for immunization. The technology also has been designed to generate new vaccines with a broad spectrum of activity against multiple strains of several different pathogens, and deliver aerosol-based preventative and therapeutic agents.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.